# ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Source: https://onco.cc/trials/nct03686124/  
OnCo record `nct03686124` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Immatics US, Inc., now recruiting.

## Summary

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors is a phase 1/2 interventional study registered as NCT03686124 by Immatics US, Inc., with 375 participants planned, started 2019-05-14 and due to reach its primary completion in 2028-12. Interventions recorded: IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product, Nivolumab and IMADetect®.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03686124
- Phase: 1/2
- Setting: Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
- Sponsor: Immatics US, Inc.
- Enrolled: 375

## Sources

- ClinicalTrials.gov NCT03686124: https://clinicaltrials.gov/study/NCT03686124

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Immatics](https://onco.cc/companies/immatics/)

---
JSON: https://onco.cc/api/v1/entities/nct03686124.json